OHR Pharmaceutical (OHRP) Hits New 12-Month High and Low Following Better-Than-Expected Earnings

OHR Pharmaceutical Inc (NASDAQ:OHRP)’s share price hit a new 52-week high and low on Wednesday following a better than expected earnings announcement. The stock traded as low as $0.19 and last traded at $0.19, with a volume of 700 shares changing hands. The stock had previously closed at $0.19.

The biotechnology company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.02.

Separately, ValuEngine raised shares of OHR Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

An institutional investor recently raised its position in OHR Pharmaceutical stock. Wedbush Securities Inc. boosted its holdings in shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) by 53.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 662,909 shares of the biotechnology company’s stock after purchasing an additional 230,950 shares during the period. Wedbush Securities Inc. owned approximately 1.18% of OHR Pharmaceutical worth $1,233,000 as of its most recent filing with the SEC. 8.94% of the stock is currently owned by institutional investors and hedge funds.

The stock has a market capitalization of $11.40 million, a PE ratio of -0.36 and a beta of 0.14.

OHR Pharmaceutical Company Profile

OHR Pharmaceutical, Inc, a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.

Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply